» Articles » PMID: 23954793

High Dose Remifentanil Increases Myocardial Oxidative Stress and Compromises Remifentanil Infarct-sparing Effects in Rats

Overview
Journal Eur J Pharmacol
Specialty Pharmacology
Date 2013 Aug 20
PMID 23954793
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic administration of high dose opioids such as morphine is known to create intracellular oxidative stress via an opioid receptor dependent mechanism and this can interfere with cellular function. This study aimed at examining whether such changes can occur following short term exposure to high concentration of remifentanil, a potent short acting opioid. We conducted a experimental study using rat myocardium and systematically quantified tissue levels of superoxide anions, malondialdehyde (MDA) and nitrotyrosine following exposure to increasing duration (15 min, 1 or 2 h) or escalating doses of remifentanil (1 μg, 5 μg, 10 μg or 20 μg/kg/min). Concurrently the susceptibility of the heart to ischaemia reperfusion injury was assessed under the similar conditions. For any given duration of remifentanil infusion, there was increasing superoxide anions generated as the dose of remifentanil was increased. MDA concentrations were significantly increased when the animal was exposed to 10 μg/kg/min for 2h or 20 μg/kg/min for any duration. There was a trend towards an increased nitrotyrosine concentration with increasing dose of remifentanil, becoming significant when the dose was 20 μg/kg/min. The infarct limiting ability of remifentanil was compromised when the dihydroethidium fluorescence positive cell percentage exceeded 50%, MDA concentration greater than 2 nmol/mg of protein and nitrotyrosine content exceeding 1.5 μg/mg of protein. Short term high dose opioid exposure can induce oxidative changes seen previously only with chronic opioid use and this high oxidative stress environment corrupts the heart's sensitivity to be preconditioned by opioids.

Citing Articles

High-dose remifentanil exacerbates myocardial ischemia-reperfusion injury through activation of calcium-sensing receptor-mediated pyroptosis.

Zhu Y, Chi J, Cai S, Liu S, Yuan J, Xu H Int J Med Sci. 2023; 20(12):1570-1583.

PMID: 37859698 PMC: 10583183. DOI: 10.7150/ijms.83207.


Prescribed opioid use is associated with adverse cardiovascular outcomes in community-dwelling older persons.

Liew S, Chowdhury E, Ernst M, Gilmartin-Thomas J, Reid C, Tonkin A ESC Heart Fail. 2022; 9(6):3973-3984.

PMID: 35985663 PMC: 9773735. DOI: 10.1002/ehf2.14101.


Effects of remifentanil and propofol on distant organ lung injury in an ischemia-reperfusion model.

Kanbak O, Aydogan B, Gumus T Open Med (Wars). 2021; 16(1):1673-1680.

PMID: 34761118 PMC: 8576613. DOI: 10.1515/med-2021-0381.


Systemic Administration of Tempol Attenuates the Cardiorespiratory Depressant Effects of Fentanyl.

Baby S, Gruber R, Discala J, Puskovic V, Jose N, Cheng F Front Pharmacol. 2021; 12:690407.

PMID: 34248639 PMC: 8260831. DOI: 10.3389/fphar.2021.690407.


Remifentanil preconditioning protects against hypoxia-induced senescence and necroptosis in human cardiac myocytes .

Lewinska A, Adamczyk-Grochala J, Bloniarz D, Horeczy B, Zurek S, Kurowicki A Aging (Albany NY). 2020; 12(14):13924-13938.

PMID: 32584786 PMC: 7425462. DOI: 10.18632/aging.103604.